Based on these studies, a phase I study was conducted with CD137L-expressing DCs that were pulsed with a peptide mix of EBV LMP1, LMP2, and LMP2A as a vaccination for NPC patients. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.